Navigation Links
ViroPharma to Participate in Two December Healthcare Investor Conferences
Date:12/5/2011

EXTON, Pa., Dec. 5, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Robert Doody, assistant director of investor relations of ViroPharma, will present at the 2011 Deutsche Bank BioFEST Conference at 8:35 A.M. ET on Tuesday, December 6, 2011.  The conference is being held at the Four Seasons Hotel in Boston.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Oppenheimer 22nd Annual Healthcare Conference at 4:30 P.M. ET on Tuesday, December 13, 2011.  The conference is being held at the Waldorf Astoria Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.

 


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: ... committed to progressing its ground-breaking technology platforms to Phase ... ensure the Company delivers the best value for shareholders. ... , said the Company currently had an extensive program ... programs and academic partnerships and initiatives, and he was ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... to File Appeal, BERKELEY HEIGHTS, N.J., Jan. ... today that the Company has received,notice from the ... based upon the Company,s non-compliance with the stockholders, ... the Company,s,common stock is subject to delisting from ...
... YORK, Jan. 11 "I am pleased to announce ... Ltd. and Kemfast,Ltd (collectively Kemfast) and its MC Technologies ... L.P. to form Haas TCM Group Inc.,ICMS Holdings, Inc. ... be integrated with Haas TCM Group Inc. The focus ...
... ... the Term ,Bio-identical, SPOKANE, Wash., Jan. 11 "The ... --,progesterone, and other compounded hormones was very surprising to me ... Cheryle,Hart, M.D. She is Mayo Clinic trained and Board certified ...
Cached Biology Technology:Genta Receives Notice of Non-Compliance With NASDAQ Rule 2Genta Receives Notice of Non-Compliance With NASDAQ Rule 3The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc. 2The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc. 3Bio-Identical Hormone Menopause Doctor Responds to Outrageous FDA News 2
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, ... expected revenues in 2015 that relate to sales of FPC1025 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... in China and we are proud that ... for Axon , its first ...
(Date:7/13/2015)... Conn. , Jul. 13, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/188684 for ... achieves another new convenient and secure method to ... new, innovative payment methods, introduced with its groundbreaking ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... Biologically Inspired Engineering at Harvard University have developed ... toughness, and versatility of one of nature,s more ... the new material, called "Shrilk," could one day ... safely in a variety of medical applications. ...
... is available in German . Plants ... through photosynthesis in the leaves. However, they do not have ... this vital fuel. Instead, they use pump proteins in their ... Carnegie Institution for Science in California, Alisdair Fernie from the ...
... a native frog rising in the West. With a ... Davidson has young children imagining the life cycles and life ... cheering for the underfrog. "Cheery: The true adventures of ... Davidson and brought to life by graphic artist Michael Hagelberg. ...
Cached Biology News:Inspired by insect cuticle, Wyss Institute develops material that's tough and strong 2Sugar pump in plants identified 2Sugar pump in plants identified 3Picture book portrays a 'hoppy' future for endangered frogs 2Picture book portrays a 'hoppy' future for endangered frogs 3
... Custom peptide microarrays designed for quantitative ... samples and built on the flexible ... Thousands of customer specified sequences can ... can provide assistance with custom sequence ...
... for OPA1-01009, OPEP-01009 is a 16 amino acid (amino acids ... factor (DFF). The sequence of this peptide is (amino ... - S - V - K - L - R ... - R - K(18). This peptide may be ...
... Arrays are intended for laboratory research use ... in neutral buffered formalin and embedded in ... performed by certified pathologists. Tissue cores ... relocated into a new recipient paraffin block, ...
... Processing of Microarrays Using the New FAST(tm) ... slide plate is designed to hold four, ... incubation chambers in a microplate footprint for ... dimensions meet the standards recommended by the ...
Biology Products: